Juravinski Cancer Centre

Juravinski Hospital

Hamilton, ON

Sorting 3 by

Not yet accepting

QUINTESSENTIAL-2

Phase 3 Clinical Trial Comparing the Safety and Efficacy of BMS-986393 to Standard of Care Regimens in Patients with Relapsed/Refractory Multiple Myeloma
  • CAR T Cell
  • GPRC5D
  • Randomization
  • Phase 3

Accepting patients

Etentamig

A Study to Assess Adverse Events of Intravenously (IV) Infused ABBV-383 in Adult Participants With Relapsed or Refractory Multiple Myeloma
  • Bispecific Antibody
  • BCMA
  • Phase 1
  • Has results

Accepting patients

AZD0305

AZD0305 as Monotherapy or in Combination With Anticancer Agents in Participants With Relapsed/​Refractory Multiple Myeloma
  • Antibody Drug Conjugate (ADC)
  • GPRC5D
  • Phase 1/2